Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

1 hour ago 2

MarketBeat

Tue, June 9, 2026 astatine 10:06 AM CDT 6 min read

Key Points

Interested successful Amgen Inc.? Here are 5 stocks we similar better.
Amgen said its beardown first-quarter results enactment the thought that 2026 could beryllium a “springboard year”, with gross up 6% and EPS up 5% arsenic maturation products offset patent and exclusivity unit connected older drugs.
The institution highlighted respective large maturation drivers — including Repatha, EVENITY, TEZSPIRE, oncology, uncommon illness and biosimilars — which unneurotic made up astir 70% of first-quarter merchandise income and grew 24% twelvemonth implicit year.
Amgen is besides leaning connected its pipeline, particularly MariTide for obesity and diabetes, positive late-stage programs similar olpasiran and xaluritamig, portion continuing to grow UPLIZNA and different rare-disease launches.

Ozempic, Mounjaro, Wegovy, oregon Zepbound? This ETF Holds Them All

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter show supports its presumption that 2026 tin service arsenic a “springboard year,” with maturation products helping offset accrued contention for the denosumab franchise and different losses of exclusivity.

Speaking astatine a Goldman Sachs event, Peter Griffith, Amgen’s main fiscal officer, said first-quarter gross roseate 6% year-over-year and non-GAAP net per stock accrued 5%. He said 16 products delivered double-digit oregon amended income growth, portion 17 products were annualizing astatine much than $1 cardinal successful merchandise income based connected first-quarter results.

→ Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Griffith said six cardinal maturation drivers — Repatha, EVENITY, TEZSPIRE, the company’s innovative oncology portfolio, uncommon illness portfolio and biosimilars portfolio — accounted for astir 70% of merchandise income successful the archetypal 4th and grew 24% arsenic a radical year-over-year.

Executives Point to Breadth of Growth Drivers

Murdo Gordon, caput of planetary commercialized operations, said Amgen has a “set of prioritized maturation drivers” that helium believes tin assistance the institution negociate the interaction of existent and aboriginal losses of exclusivity, including denosumab and Otezla successful Europe.

→ Meta Unveils Subscriptions: A New Offering With Real Growth Potential

5 Healthcare Names to Watch arsenic Sector Rotation Is successful Full Swing

Andrew Martin, caput of U.S. concern operations, highlighted Repatha, IMDELLTRA, PAVBLU and TEZSPIRE arsenic large areas of commercialized opportunity. On Repatha, Martin said determination are much than 100 cardinal radical globally with elevated LDL, including astir 50 cardinal successful the United States, and that PCSK9 penetration remains astir 10% oregon somewhat beneath among the applicable diligent population.

Read Entire Article